Zener, Rebecca
Yoon, Hyukjun
Ziv, Etay
Covey, Anne
Brown, Karen T.
Sofocleous, Constantinos T.
Thornton, Raymond H.
Boas, F. Edward http://orcid.org/0000-0002-1382-5365
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 10 September 2018
Accepted: 31 December 2018
First Online: 9 January 2019
Compliance with Ethical Standards
:
: FEB is a co-founder of Claripacs, LLC. He received research funding (investigator-initiated) and support for research meetings from Guerbet. He received research support (investigator-initiated) from GE. He received research supplies (investigator-initiated) from Bayer. He received a research grant and speaker fees from Society of Interventional Oncology, which were sponsored by Guerbet. He is an investor in Labdoor, Qventus, CloudMedx, and Notable Labs. AC is on the advisory board for Accurate Medical and is a stockholder in Amgen. EZ received an investigator-initiated industry research grant from Johnson & Johnson and has a pending investigator-initiated research grant from AAA-Novartis.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This HIPAA-compliant retrospective study was approved by the IRB.
: For this type of study, informed consent is not required. This study has obtained IRB approval from Memorial Sloan Kettering Cancer Center, and the need for informed consent was waived.